AbbVie has applied to the European Medicines Agency for marketing authorization of atogepant for the prevention of migraine in adult patients with at least four days of attacks per month. If approved, atogepant will be the first daily oral CGRP receptor antagonist for the prevention of migraine in adult patients in Europe.